| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 94 | 2024 | 1204 | 14.010 |
Why?
|
| Heart-Assist Devices | 73 | 2023 | 731 | 10.410 |
Why?
|
| Heart Transplantation | 67 | 2023 | 705 | 10.380 |
Why?
|
| Tissue and Organ Procurement | 8 | 2023 | 311 | 2.450 |
Why?
|
| Ventricular Function, Left | 20 | 2024 | 592 | 2.170 |
Why?
|
| Pneumonia, Viral | 10 | 2020 | 316 | 2.070 |
Why?
|
| Coronavirus Infections | 10 | 2020 | 301 | 2.070 |
Why?
|
| Ventricular Dysfunction, Right | 6 | 2023 | 134 | 2.010 |
Why?
|
| Tissue Donors | 13 | 2023 | 464 | 1.900 |
Why?
|
| Tricuspid Valve Insufficiency | 6 | 2023 | 111 | 1.870 |
Why?
|
| Defibrillators, Implantable | 8 | 2021 | 129 | 1.600 |
Why?
|
| Humans | 181 | 2024 | 86678 | 1.570 |
Why?
|
| Blood Pressure Determination | 2 | 2022 | 90 | 1.490 |
Why?
|
| Heart Ventricles | 9 | 2023 | 760 | 1.350 |
Why?
|
| Registries | 7 | 2023 | 703 | 1.330 |
Why?
|
| Graft Rejection | 8 | 2021 | 1065 | 1.310 |
Why?
|
| Shock, Cardiogenic | 9 | 2023 | 95 | 1.300 |
Why?
|
| Waiting Lists | 12 | 2023 | 175 | 1.220 |
Why?
|
| Betacoronavirus | 8 | 2020 | 258 | 1.190 |
Why?
|
| Myocardial Infarction | 6 | 2020 | 376 | 1.170 |
Why?
|
| Retrospective Studies | 48 | 2023 | 8496 | 1.100 |
Why?
|
| Acute Kidney Injury | 2 | 2021 | 296 | 1.090 |
Why?
|
| Middle Aged | 82 | 2024 | 25040 | 1.070 |
Why?
|
| Postoperative Complications | 14 | 2022 | 2207 | 1.050 |
Why?
|
| Aortic Valve Insufficiency | 2 | 2023 | 130 | 1.010 |
Why?
|
| Ventricular Dysfunction, Left | 9 | 2023 | 318 | 1.000 |
Why?
|
| Male | 91 | 2024 | 40988 | 0.990 |
Why?
|
| Prosthesis Implantation | 11 | 2020 | 125 | 0.980 |
Why?
|
| Stroke Volume | 14 | 2024 | 456 | 0.960 |
Why?
|
| Prosthesis-Related Infections | 2 | 2021 | 58 | 0.930 |
Why?
|
| Female | 89 | 2024 | 44550 | 0.910 |
Why?
|
| Hypertension, Pulmonary | 6 | 2016 | 346 | 0.900 |
Why?
|
| Cardiovascular System | 1 | 2023 | 71 | 0.900 |
Why?
|
| Prognosis | 20 | 2022 | 3680 | 0.870 |
Why?
|
| Heart | 7 | 2023 | 539 | 0.860 |
Why?
|
| Quality of Life | 12 | 2024 | 1585 | 0.860 |
Why?
|
| Cardiomyopathies | 6 | 2023 | 240 | 0.840 |
Why?
|
| Vasoplegia | 1 | 2021 | 1 | 0.830 |
Why?
|
| Treatment Outcome | 44 | 2023 | 7998 | 0.820 |
Why?
|
| Myocarditis | 3 | 2020 | 51 | 0.810 |
Why?
|
| Heart Valve Prosthesis Implantation | 4 | 2023 | 166 | 0.800 |
Why?
|
| Extracorporeal Membrane Oxygenation | 3 | 2022 | 140 | 0.800 |
Why?
|
| Hemodynamics | 11 | 2023 | 711 | 0.790 |
Why?
|
| Civil Defense | 1 | 2020 | 11 | 0.760 |
Why?
|
| Hospital Bed Capacity | 1 | 2020 | 20 | 0.760 |
Why?
|
| Mortality | 1 | 2021 | 149 | 0.750 |
Why?
|
| Patient Care Management | 1 | 2020 | 31 | 0.750 |
Why?
|
| Aged | 46 | 2024 | 18423 | 0.740 |
Why?
|
| Electric Countershock | 3 | 2019 | 47 | 0.720 |
Why?
|
| Pandemics | 11 | 2020 | 740 | 0.700 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 169 | 0.660 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 231 | 0.650 |
Why?
|
| Follow-Up Studies | 16 | 2020 | 3642 | 0.650 |
Why?
|
| Donor Selection | 2 | 2022 | 68 | 0.640 |
Why?
|
| Cardiology | 2 | 2020 | 123 | 0.640 |
Why?
|
| Blood Pressure | 3 | 2022 | 1144 | 0.630 |
Why?
|
| New York City | 10 | 2020 | 59 | 0.630 |
Why?
|
| Renal Dialysis | 3 | 2021 | 355 | 0.630 |
Why?
|
| Health Care Rationing | 2 | 2018 | 83 | 0.630 |
Why?
|
| Risk Factors | 23 | 2020 | 5420 | 0.620 |
Why?
|
| Adult | 49 | 2023 | 25659 | 0.610 |
Why?
|
| Resource Allocation | 1 | 2017 | 65 | 0.600 |
Why?
|
| Tricuspid Valve | 4 | 2023 | 96 | 0.600 |
Why?
|
| Cardiomyopathy, Dilated | 9 | 2017 | 97 | 0.600 |
Why?
|
| Cardiovascular Diseases | 5 | 2023 | 827 | 0.590 |
Why?
|
| Isoantibodies | 2 | 2019 | 114 | 0.590 |
Why?
|
| HLA Antigens | 5 | 2022 | 232 | 0.580 |
Why?
|
| Mitral Valve Insufficiency | 5 | 2023 | 187 | 0.570 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2017 | 187 | 0.550 |
Why?
|
| Biomedical Technology | 1 | 2015 | 20 | 0.530 |
Why?
|
| Organ Transplantation | 4 | 2023 | 265 | 0.530 |
Why?
|
| Frailty | 3 | 2023 | 58 | 0.530 |
Why?
|
| Lung Transplantation | 3 | 2023 | 175 | 0.510 |
Why?
|
| Cardiotonic Agents | 1 | 2015 | 88 | 0.510 |
Why?
|
| United States | 13 | 2023 | 6681 | 0.510 |
Why?
|
| Myocardium | 5 | 2020 | 529 | 0.500 |
Why?
|
| Assisted Circulation | 1 | 2014 | 15 | 0.490 |
Why?
|
| Parenteral Nutrition | 1 | 2014 | 60 | 0.490 |
Why?
|
| Natriuretic Peptides | 1 | 2013 | 6 | 0.480 |
Why?
|
| Troponin | 1 | 2013 | 24 | 0.470 |
Why?
|
| Risk Assessment | 8 | 2020 | 2264 | 0.470 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2014 | 68 | 0.460 |
Why?
|
| Ventricular Remodeling | 3 | 2023 | 96 | 0.460 |
Why?
|
| Mitral Valve | 5 | 2018 | 248 | 0.460 |
Why?
|
| Histocompatibility Testing | 1 | 2013 | 154 | 0.450 |
Why?
|
| Cardiac Valve Annuloplasty | 3 | 2023 | 13 | 0.450 |
Why?
|
| Practice Guidelines as Topic | 4 | 2020 | 1037 | 0.440 |
Why?
|
| Pulsatile Flow | 1 | 2012 | 49 | 0.430 |
Why?
|
| Bacteremia | 3 | 2019 | 99 | 0.420 |
Why?
|
| Advance Care Planning | 3 | 2021 | 43 | 0.420 |
Why?
|
| Heart Rate | 4 | 2022 | 492 | 0.410 |
Why?
|
| Incidence | 11 | 2021 | 1578 | 0.400 |
Why?
|
| Cardiac Surgical Procedures | 8 | 2017 | 462 | 0.400 |
Why?
|
| Policy Making | 1 | 2011 | 62 | 0.400 |
Why?
|
| Societies, Medical | 4 | 2020 | 573 | 0.400 |
Why?
|
| Patient Selection | 6 | 2020 | 686 | 0.400 |
Why?
|
| Renal Insufficiency | 2 | 2011 | 114 | 0.400 |
Why?
|
| Heart Diseases | 4 | 2018 | 290 | 0.390 |
Why?
|
| Disseminated Intravascular Coagulation | 2 | 2010 | 27 | 0.390 |
Why?
|
| Immunosuppressive Agents | 8 | 2020 | 977 | 0.390 |
Why?
|
| Coronary Vessels | 2 | 2004 | 177 | 0.390 |
Why?
|
| Time Factors | 15 | 2020 | 5214 | 0.380 |
Why?
|
| Atrial Fibrillation | 1 | 2014 | 288 | 0.380 |
Why?
|
| Biomarkers | 7 | 2020 | 1718 | 0.370 |
Why?
|
| Glucosides | 2 | 2020 | 20 | 0.360 |
Why?
|
| Aftercare | 4 | 2024 | 85 | 0.360 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2010 | 50 | 0.360 |
Why?
|
| Survival Rate | 7 | 2022 | 1864 | 0.360 |
Why?
|
| Cohort Studies | 9 | 2022 | 2768 | 0.360 |
Why?
|
| Benzhydryl Compounds | 2 | 2020 | 48 | 0.360 |
Why?
|
| Hospitalization | 8 | 2023 | 851 | 0.350 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2009 | 9 | 0.350 |
Why?
|
| Thrombosis | 4 | 2018 | 296 | 0.350 |
Why?
|
| Ventricular Function, Right | 5 | 2023 | 142 | 0.340 |
Why?
|
| Consensus | 6 | 2022 | 336 | 0.340 |
Why?
|
| Prosthesis Design | 8 | 2020 | 278 | 0.340 |
Why?
|
| Kidney | 3 | 2023 | 1242 | 0.340 |
Why?
|
| Young Adult | 11 | 2020 | 5980 | 0.340 |
Why?
|
| Walking | 1 | 2009 | 87 | 0.330 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2009 | 107 | 0.330 |
Why?
|
| Terminology as Topic | 3 | 2014 | 217 | 0.320 |
Why?
|
| Echocardiography | 8 | 2020 | 911 | 0.300 |
Why?
|
| Tachycardia, Ventricular | 2 | 2019 | 115 | 0.300 |
Why?
|
| Acute Disease | 4 | 2023 | 826 | 0.290 |
Why?
|
| Prospective Studies | 14 | 2020 | 4214 | 0.290 |
Why?
|
| Cardiovascular Agents | 4 | 2019 | 56 | 0.280 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2006 | 73 | 0.280 |
Why?
|
| Exercise | 1 | 2009 | 315 | 0.280 |
Why?
|
| Heart Defects, Congenital | 4 | 2019 | 351 | 0.280 |
Why?
|
| Disease Progression | 6 | 2019 | 1532 | 0.270 |
Why?
|
| Sirolimus | 2 | 2004 | 170 | 0.270 |
Why?
|
| Gene Expression Profiling | 3 | 2020 | 1384 | 0.270 |
Why?
|
| Patient Readmission | 2 | 2020 | 329 | 0.260 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2005 | 9 | 0.260 |
Why?
|
| Hepatitis B Antibodies | 1 | 2005 | 15 | 0.260 |
Why?
|
| Adolescent | 9 | 2020 | 8984 | 0.260 |
Why?
|
| Staphylococcal Infections | 3 | 2017 | 255 | 0.260 |
Why?
|
| Benchmarking | 2 | 2023 | 79 | 0.250 |
Why?
|
| American Heart Association | 2 | 2022 | 92 | 0.250 |
Why?
|
| Rituximab | 2 | 2019 | 116 | 0.250 |
Why?
|
| Graft Survival | 3 | 2023 | 885 | 0.250 |
Why?
|
| Palliative Care | 2 | 2023 | 257 | 0.250 |
Why?
|
| Aorta | 2 | 2021 | 281 | 0.240 |
Why?
|
| Magnetic Resonance Imaging, Cine | 4 | 2023 | 159 | 0.240 |
Why?
|
| Minocycline | 1 | 2003 | 15 | 0.240 |
Why?
|
| Immunologic Factors | 2 | 2019 | 170 | 0.230 |
Why?
|
| Hospital Mortality | 4 | 2023 | 350 | 0.230 |
Why?
|
| Atrioventricular Block | 1 | 2023 | 23 | 0.230 |
Why?
|
| Tunica Intima | 1 | 2003 | 59 | 0.230 |
Why?
|
| Survival Analysis | 9 | 2014 | 1538 | 0.230 |
Why?
|
| Transplant Recipients | 2 | 2023 | 122 | 0.230 |
Why?
|
| Patient Discharge | 5 | 2024 | 300 | 0.220 |
Why?
|
| Angioplasty, Balloon | 1 | 2003 | 95 | 0.220 |
Why?
|
| Death | 1 | 2023 | 73 | 0.220 |
Why?
|
| Abortion, Legal | 1 | 2023 | 25 | 0.220 |
Why?
|
| Perfusion | 1 | 2023 | 203 | 0.220 |
Why?
|
| Severity of Illness Index | 9 | 2022 | 1802 | 0.220 |
Why?
|
| Aortic Valve | 3 | 2021 | 222 | 0.220 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 1376 | 0.220 |
Why?
|
| Transplants | 1 | 2023 | 40 | 0.220 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2003 | 234 | 0.210 |
Why?
|
| Cardiac Catheterization | 6 | 2023 | 291 | 0.210 |
Why?
|
| Anticoagulants | 2 | 2009 | 408 | 0.210 |
Why?
|
| Cell Division | 1 | 2003 | 696 | 0.210 |
Why?
|
| Emergencies | 2 | 2019 | 113 | 0.210 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2002 | 41 | 0.210 |
Why?
|
| Ultrasonography, Doppler | 1 | 2022 | 80 | 0.200 |
Why?
|
| Biopsy | 4 | 2020 | 1163 | 0.200 |
Why?
|
| Surgical Wound Infection | 2 | 2017 | 184 | 0.200 |
Why?
|
| Aortic Diseases | 1 | 2002 | 100 | 0.200 |
Why?
|
| Aortic Rupture | 1 | 2022 | 55 | 0.200 |
Why?
|
| Preoperative Period | 1 | 2021 | 91 | 0.200 |
Why?
|
| Arteries | 1 | 2002 | 177 | 0.200 |
Why?
|
| Staphylococcus | 2 | 2017 | 24 | 0.200 |
Why?
|
| End Stage Liver Disease | 1 | 2022 | 62 | 0.200 |
Why?
|
| Disease Management | 3 | 2021 | 327 | 0.200 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2022 | 93 | 0.190 |
Why?
|
| Intersectoral Collaboration | 1 | 2020 | 10 | 0.190 |
Why?
|
| Valsartan | 1 | 2020 | 20 | 0.190 |
Why?
|
| Ventricular Dysfunction | 1 | 2020 | 28 | 0.190 |
Why?
|
| Comorbidity | 3 | 2020 | 944 | 0.190 |
Why?
|
| Aminobutyrates | 1 | 2020 | 13 | 0.190 |
Why?
|
| Cytomegalovirus | 1 | 2020 | 76 | 0.190 |
Why?
|
| Heart Valve Prosthesis | 2 | 2018 | 93 | 0.190 |
Why?
|
| Kidney Failure, Chronic | 2 | 2021 | 509 | 0.190 |
Why?
|
| Endocardium | 2 | 2012 | 76 | 0.190 |
Why?
|
| Hemodynamic Monitoring | 1 | 2020 | 8 | 0.190 |
Why?
|
| Biphenyl Compounds | 1 | 2020 | 68 | 0.190 |
Why?
|
| Troponin I | 1 | 2020 | 27 | 0.190 |
Why?
|
| Electronic Health Records | 3 | 2020 | 320 | 0.190 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2020 | 49 | 0.190 |
Why?
|
| Recovery of Function | 5 | 2020 | 272 | 0.180 |
Why?
|
| Coronary Artery Disease | 2 | 2004 | 350 | 0.180 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2020 | 80 | 0.180 |
Why?
|
| Cell Movement | 1 | 2003 | 758 | 0.180 |
Why?
|
| Cytomegalovirus Infections | 1 | 2020 | 144 | 0.180 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2019 | 44 | 0.180 |
Why?
|
| Psychology | 1 | 2019 | 24 | 0.170 |
Why?
|
| Thoracic Surgery | 1 | 2020 | 43 | 0.170 |
Why?
|
| Patient Transfer | 1 | 2020 | 91 | 0.170 |
Why?
|
| Emergency Treatment | 1 | 2019 | 39 | 0.170 |
Why?
|
| Cross Infection | 1 | 2020 | 141 | 0.170 |
Why?
|
| Reoperation | 4 | 2014 | 597 | 0.170 |
Why?
|
| Metabolic Syndrome | 1 | 2020 | 142 | 0.170 |
Why?
|
| Heart Function Tests | 1 | 2018 | 30 | 0.170 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2019 | 272 | 0.170 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2018 | 16 | 0.170 |
Why?
|
| Exercise Test | 2 | 2020 | 164 | 0.170 |
Why?
|
| Echocardiography, Doppler | 1 | 2019 | 187 | 0.160 |
Why?
|
| Electrocardiography | 3 | 2020 | 478 | 0.160 |
Why?
|
| Emergency Medicine | 1 | 2020 | 123 | 0.160 |
Why?
|
| Patient Care | 1 | 2019 | 100 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2014 | 861 | 0.160 |
Why?
|
| Transplantation, Homologous | 3 | 2020 | 996 | 0.160 |
Why?
|
| Vascular Diseases | 1 | 2019 | 121 | 0.160 |
Why?
|
| Churg-Strauss Syndrome | 1 | 2018 | 9 | 0.160 |
Why?
|
| Proportional Hazards Models | 4 | 2019 | 860 | 0.160 |
Why?
|
| Heart, Artificial | 1 | 2017 | 9 | 0.160 |
Why?
|
| Bacterial Infections | 1 | 2019 | 182 | 0.160 |
Why?
|
| Catheter-Related Infections | 1 | 2017 | 23 | 0.160 |
Why?
|
| Mediastinitis | 2 | 2017 | 14 | 0.160 |
Why?
|
| Referral and Consultation | 2 | 2023 | 328 | 0.160 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2019 | 71 | 0.160 |
Why?
|
| Heart Failure, Systolic | 1 | 2017 | 7 | 0.160 |
Why?
|
| Sternum | 2 | 2007 | 30 | 0.160 |
Why?
|
| Forecasting | 1 | 2019 | 305 | 0.150 |
Why?
|
| Creatinine | 3 | 2023 | 339 | 0.150 |
Why?
|
| Physician's Role | 1 | 2019 | 179 | 0.150 |
Why?
|
| Heart-Lung Transplantation | 1 | 2017 | 17 | 0.150 |
Why?
|
| Fatal Outcome | 3 | 2020 | 295 | 0.150 |
Why?
|
| Primary Graft Dysfunction | 1 | 2017 | 27 | 0.150 |
Why?
|
| Anti-Bacterial Agents | 4 | 2019 | 747 | 0.150 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 84 | 0.150 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 429 | 0.150 |
Why?
|
| Benzazepines | 1 | 2017 | 89 | 0.150 |
Why?
|
| Frail Elderly | 1 | 2017 | 71 | 0.150 |
Why?
|
| Health Status Disparities | 1 | 2019 | 170 | 0.150 |
Why?
|
| Preoperative Care | 1 | 2019 | 397 | 0.150 |
Why?
|
| Pulmonary Wedge Pressure | 4 | 2021 | 108 | 0.140 |
Why?
|
| Ventricular Septum | 1 | 2016 | 11 | 0.140 |
Why?
|
| Emergency Medical Services | 1 | 2019 | 209 | 0.140 |
Why?
|
| Transcriptome | 1 | 2020 | 580 | 0.140 |
Why?
|
| Oxygen Consumption | 2 | 2015 | 239 | 0.140 |
Why?
|
| Multivariate Analysis | 3 | 2013 | 1001 | 0.130 |
Why?
|
| Heart Arrest | 1 | 2019 | 265 | 0.130 |
Why?
|
| Pulmonary Artery | 5 | 2021 | 306 | 0.130 |
Why?
|
| New York | 3 | 2019 | 69 | 0.130 |
Why?
|
| Ascites | 1 | 2015 | 56 | 0.130 |
Why?
|
| Anxiety | 1 | 2017 | 287 | 0.130 |
Why?
|
| Terfenadine | 1 | 1995 | 22 | 0.130 |
Why?
|
| Aged, 80 and over | 7 | 2024 | 6513 | 0.130 |
Why?
|
| Catheter Ablation | 1 | 2017 | 233 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 455 | 0.130 |
Why?
|
| Machine Learning | 1 | 2017 | 232 | 0.120 |
Why?
|
| Coronary Angiography | 4 | 2020 | 232 | 0.120 |
Why?
|
| Cardio-Renal Syndrome | 1 | 2013 | 6 | 0.120 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 610 | 0.120 |
Why?
|
| Lipocalin-2 | 1 | 2013 | 38 | 0.120 |
Why?
|
| Lipocalins | 1 | 2013 | 35 | 0.120 |
Why?
|
| Cystatin C | 1 | 2013 | 31 | 0.120 |
Why?
|
| Acute-Phase Proteins | 1 | 2013 | 37 | 0.120 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 426 | 0.120 |
Why?
|
| Monitoring, Ambulatory | 1 | 2013 | 32 | 0.120 |
Why?
|
| Chagas Disease | 1 | 2013 | 3 | 0.120 |
Why?
|
| Pain | 1 | 2016 | 391 | 0.120 |
Why?
|
| Depression | 1 | 2017 | 473 | 0.120 |
Why?
|
| Device Removal | 2 | 2012 | 161 | 0.120 |
Why?
|
| Coronary Vasospasm | 2 | 2005 | 12 | 0.120 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2013 | 4 | 0.120 |
Why?
|
| Equipment Failure | 1 | 2013 | 119 | 0.110 |
Why?
|
| Feasibility Studies | 3 | 2021 | 751 | 0.110 |
Why?
|
| Chronic Disease | 2 | 2013 | 973 | 0.110 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 1673 | 0.110 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 364 | 0.110 |
Why?
|
| Emigrants and Immigrants | 1 | 2013 | 44 | 0.110 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2020 | 231 | 0.110 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2014 | 237 | 0.100 |
Why?
|
| Aneurysm, Infected | 1 | 2011 | 12 | 0.100 |
Why?
|
| Prosthesis Failure | 1 | 2012 | 111 | 0.100 |
Why?
|
| Calcineurin Inhibitors | 1 | 2012 | 54 | 0.100 |
Why?
|
| Cardiac Output | 2 | 2022 | 156 | 0.100 |
Why?
|
| Postoperative Hemorrhage | 1 | 2012 | 46 | 0.100 |
Why?
|
| Nephrosclerosis | 1 | 2011 | 7 | 0.100 |
Why?
|
| Single-Blind Method | 2 | 2024 | 153 | 0.100 |
Why?
|
| Child | 4 | 2018 | 6928 | 0.100 |
Why?
|
| Cardiac Myosins | 1 | 2011 | 18 | 0.100 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2011 | 38 | 0.100 |
Why?
|
| Aneurysm, False | 1 | 2011 | 54 | 0.100 |
Why?
|
| Tacrolimus | 2 | 2018 | 373 | 0.100 |
Why?
|
| Aortic Aneurysm | 1 | 2011 | 80 | 0.100 |
Why?
|
| Double-Blind Method | 3 | 2020 | 1824 | 0.100 |
Why?
|
| Telemedicine | 1 | 2013 | 169 | 0.100 |
Why?
|
| Speech | 2 | 2021 | 84 | 0.100 |
Why?
|
| Propensity Score | 2 | 2022 | 136 | 0.100 |
Why?
|
| Reference Standards | 2 | 2023 | 159 | 0.100 |
Why?
|
| Autoantibodies | 3 | 2011 | 267 | 0.100 |
Why?
|
| Transplantation Tolerance | 1 | 2012 | 130 | 0.090 |
Why?
|
| Staphylococcus aureus | 1 | 2013 | 263 | 0.090 |
Why?
|
| Myocardial Contraction | 1 | 2011 | 244 | 0.090 |
Why?
|
| Alanine Transaminase | 1 | 2010 | 73 | 0.090 |
Why?
|
| Aspartate Aminotransferases | 1 | 2010 | 73 | 0.090 |
Why?
|
| Surveys and Questionnaires | 4 | 2020 | 2504 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 3362 | 0.090 |
Why?
|
| Thrombolytic Therapy | 1 | 2012 | 220 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 645 | 0.090 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2011 | 228 | 0.090 |
Why?
|
| Vascular Resistance | 1 | 2009 | 102 | 0.090 |
Why?
|
| Logistic Models | 1 | 2013 | 1188 | 0.090 |
Why?
|
| Systole | 1 | 2009 | 129 | 0.090 |
Why?
|
| Debridement | 3 | 2017 | 56 | 0.090 |
Why?
|
| Activities of Daily Living | 2 | 2023 | 204 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 78 | 0.090 |
Why?
|
| Animals | 5 | 2020 | 26590 | 0.090 |
Why?
|
| Endomyocardial Fibrosis | 1 | 2009 | 6 | 0.090 |
Why?
|
| Endothelium, Vascular | 1 | 2011 | 435 | 0.080 |
Why?
|
| Embolism, Amniotic Fluid | 1 | 2008 | 1 | 0.080 |
Why?
|
| Factor VIIa | 1 | 2008 | 5 | 0.080 |
Why?
|
| Myocardial Ischemia | 1 | 2010 | 162 | 0.080 |
Why?
|
| Diabetic Nephropathies | 1 | 2011 | 248 | 0.080 |
Why?
|
| Heart Valve Diseases | 1 | 2009 | 109 | 0.080 |
Why?
|
| Heart Atria | 1 | 2010 | 250 | 0.080 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2005 | 56 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2023 | 1169 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2009 | 596 | 0.080 |
Why?
|
| Pacemaker, Artificial | 2 | 2006 | 87 | 0.080 |
Why?
|
| Pyrimethamine | 1 | 2006 | 21 | 0.070 |
Why?
|
| Sulfadiazine | 1 | 2006 | 24 | 0.070 |
Why?
|
| Antiprotozoal Agents | 1 | 2006 | 33 | 0.070 |
Why?
|
| Nitrates | 1 | 2006 | 35 | 0.070 |
Why?
|
| Opportunistic Infections | 1 | 2006 | 59 | 0.070 |
Why?
|
| Communication | 2 | 2020 | 442 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2023 | 840 | 0.070 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2006 | 90 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 1621 | 0.070 |
Why?
|
| Toxoplasmosis | 1 | 2006 | 64 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2009 | 770 | 0.070 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2006 | 45 | 0.070 |
Why?
|
| Coronary Restenosis | 1 | 2005 | 11 | 0.070 |
Why?
|
| Lamivudine | 1 | 2005 | 13 | 0.060 |
Why?
|
| Coronary Circulation | 1 | 2005 | 130 | 0.060 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2005 | 99 | 0.060 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2005 | 23 | 0.060 |
Why?
|
| Hepatitis B, Chronic | 1 | 2005 | 32 | 0.060 |
Why?
|
| Kidney Transplantation | 1 | 2011 | 849 | 0.060 |
Why?
|
| Everolimus | 1 | 2004 | 40 | 0.060 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2003 | 14 | 0.060 |
Why?
|
| Catheterization | 1 | 2005 | 232 | 0.060 |
Why?
|
| Matrix Metalloproteinases | 1 | 2003 | 28 | 0.060 |
Why?
|
| Carotid Artery Injuries | 1 | 2003 | 22 | 0.060 |
Why?
|
| HIV Infections | 1 | 2012 | 772 | 0.060 |
Why?
|
| Simvastatin | 1 | 2004 | 106 | 0.060 |
Why?
|
| Ultrasonography, Interventional | 1 | 2004 | 121 | 0.060 |
Why?
|
| Supreme Court Decisions | 1 | 2023 | 9 | 0.060 |
Why?
|
| Thromboembolism | 1 | 2004 | 119 | 0.060 |
Why?
|
| Mycophenolic Acid | 2 | 2018 | 87 | 0.060 |
Why?
|
| Prevalence | 2 | 2020 | 1239 | 0.060 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2007 | 378 | 0.060 |
Why?
|
| Thorax | 1 | 2023 | 75 | 0.050 |
Why?
|
| Anticholesteremic Agents | 1 | 2004 | 137 | 0.050 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2003 | 107 | 0.050 |
Why?
|
| Multimodal Imaging | 1 | 2023 | 110 | 0.050 |
Why?
|
| Cytidine Triphosphate | 1 | 2022 | 3 | 0.050 |
Why?
|
| Action Potentials | 2 | 2017 | 573 | 0.050 |
Why?
|
| Atrial Pressure | 1 | 2021 | 6 | 0.050 |
Why?
|
| Proof of Concept Study | 1 | 2022 | 38 | 0.050 |
Why?
|
| Brain Death | 1 | 2022 | 69 | 0.050 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2022 | 78 | 0.050 |
Why?
|
| Length of Stay | 2 | 2017 | 704 | 0.050 |
Why?
|
| Contraindications | 2 | 2012 | 72 | 0.050 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2022 | 158 | 0.050 |
Why?
|
| Lung | 2 | 2004 | 1169 | 0.050 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2021 | 25 | 0.050 |
Why?
|
| Thrombophilia | 1 | 2001 | 22 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 2601 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2022 | 203 | 0.050 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2020 | 25 | 0.050 |
Why?
|
| Asymptomatic Infections | 1 | 2020 | 16 | 0.050 |
Why?
|
| Italy | 1 | 2020 | 106 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2003 | 1221 | 0.050 |
Why?
|
| Clinical Deterioration | 1 | 2020 | 19 | 0.050 |
Why?
|
| Heart Injuries | 1 | 2020 | 16 | 0.050 |
Why?
|
| Advance Directives | 1 | 2020 | 64 | 0.050 |
Why?
|
| Pregnancy | 2 | 2023 | 2894 | 0.050 |
Why?
|
| Life Expectancy | 1 | 2020 | 86 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2020 | 224 | 0.050 |
Why?
|
| Antibodies | 1 | 2022 | 350 | 0.050 |
Why?
|
| Age Factors | 2 | 2020 | 1852 | 0.050 |
Why?
|
| DNA, Viral | 1 | 2020 | 265 | 0.050 |
Why?
|
| Monitoring, Physiologic | 1 | 2021 | 268 | 0.040 |
Why?
|
| Patients | 1 | 2020 | 100 | 0.040 |
Why?
|
| Algorithms | 2 | 2019 | 1830 | 0.040 |
Why?
|
| Genome, Viral | 1 | 2020 | 74 | 0.040 |
Why?
|
| Living Donors | 1 | 2023 | 339 | 0.040 |
Why?
|
| Vimentin | 1 | 2019 | 44 | 0.040 |
Why?
|
| Walk Test | 1 | 2019 | 21 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2019 | 26 | 0.040 |
Why?
|
| Exercise Tolerance | 1 | 2019 | 48 | 0.040 |
Why?
|
| International Cooperation | 1 | 2019 | 127 | 0.040 |
Why?
|
| Allografts | 1 | 2019 | 172 | 0.040 |
Why?
|
| Myosins | 1 | 2019 | 90 | 0.040 |
Why?
|
| Postoperative Period | 2 | 2011 | 303 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 372 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2003 | 2819 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 153 | 0.040 |
Why?
|
| Immune System | 1 | 2019 | 93 | 0.040 |
Why?
|
| Cyclic Nucleotide-Gated Cation Channels | 1 | 2017 | 5 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 376 | 0.040 |
Why?
|
| Panic Disorder | 1 | 2017 | 22 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 257 | 0.040 |
Why?
|
| Prednisone | 1 | 2018 | 258 | 0.040 |
Why?
|
| Postoperative Care | 2 | 2012 | 221 | 0.040 |
Why?
|
| Critical Care | 1 | 2020 | 370 | 0.040 |
Why?
|
| Risk | 1 | 2019 | 674 | 0.040 |
Why?
|
| Sex Factors | 1 | 2020 | 1055 | 0.040 |
Why?
|
| Rats | 1 | 2003 | 3992 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2019 | 407 | 0.040 |
Why?
|
| Operative Time | 1 | 2017 | 127 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2019 | 353 | 0.040 |
Why?
|
| Self Efficacy | 1 | 2016 | 53 | 0.030 |
Why?
|
| Mass Screening | 1 | 2020 | 619 | 0.030 |
Why?
|
| Bacteria | 1 | 2019 | 447 | 0.030 |
Why?
|
| Global Health | 1 | 2017 | 193 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2017 | 487 | 0.030 |
Why?
|
| Torsades de Pointes | 1 | 1995 | 7 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2017 | 361 | 0.030 |
Why?
|
| Guinea Pigs | 1 | 1995 | 171 | 0.030 |
Why?
|
| Recurrence | 1 | 2018 | 1139 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 567 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2016 | 321 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 865 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1807 | 0.030 |
Why?
|
| Sternotomy | 1 | 2014 | 20 | 0.030 |
Why?
|
| Electrophysiology | 1 | 1995 | 401 | 0.030 |
Why?
|
| Health Status | 1 | 2016 | 360 | 0.030 |
Why?
|
| Age Distribution | 1 | 2014 | 204 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2013 | 68 | 0.030 |
Why?
|
| Trypanosoma cruzi | 1 | 2013 | 7 | 0.030 |
Why?
|
| Nitroimidazoles | 1 | 2013 | 8 | 0.030 |
Why?
|
| Infant | 2 | 2014 | 3047 | 0.030 |
Why?
|
| Aminoglycosides | 1 | 2013 | 32 | 0.030 |
Why?
|
| Vancomycin Resistance | 1 | 2013 | 18 | 0.030 |
Why?
|
| Coronary Artery Bypass | 2 | 2005 | 228 | 0.030 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2018 | 516 | 0.030 |
Why?
|
| Computational Biology | 1 | 2017 | 528 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2014 | 3613 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 1995 | 989 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2017 | 575 | 0.030 |
Why?
|
| Vancomycin | 1 | 2013 | 72 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 1995 | 912 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 1195 | 0.030 |
Why?
|
| HIV | 1 | 2012 | 46 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2012 | 286 | 0.030 |
Why?
|
| Neutrophil Infiltration | 1 | 2011 | 28 | 0.020 |
Why?
|
| Complement C4b | 1 | 2011 | 35 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2012 | 175 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2012 | 157 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 928 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2012 | 312 | 0.020 |
Why?
|
| Axillary Vein | 1 | 2010 | 5 | 0.020 |
Why?
|
| Axillary Artery | 1 | 2010 | 10 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 2357 | 0.020 |
Why?
|
| Jejunostomy | 1 | 2009 | 14 | 0.020 |
Why?
|
| Anti-HIV Agents | 1 | 2012 | 149 | 0.020 |
Why?
|
| Organ Size | 1 | 2010 | 364 | 0.020 |
Why?
|
| Observer Variation | 1 | 2011 | 603 | 0.020 |
Why?
|
| Stroke | 1 | 2018 | 965 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2011 | 460 | 0.020 |
Why?
|
| Heparin | 1 | 2009 | 175 | 0.020 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2009 | 148 | 0.020 |
Why?
|
| Obstetrical Forceps | 1 | 2008 | 9 | 0.020 |
Why?
|
| Genotype | 1 | 2013 | 1852 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2011 | 482 | 0.020 |
Why?
|
| Postpartum Hemorrhage | 1 | 2008 | 24 | 0.020 |
Why?
|
| Macrophages | 1 | 2011 | 557 | 0.020 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2008 | 104 | 0.020 |
Why?
|
| Thoracotomy | 1 | 2007 | 58 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 2062 | 0.020 |
Why?
|
| Phenotype | 1 | 2013 | 2380 | 0.020 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 1 | 2007 | 35 | 0.020 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2006 | 18 | 0.020 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2006 | 17 | 0.020 |
Why?
|
| Lipoproteins | 1 | 2007 | 135 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 3030 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 2006 | 90 | 0.020 |
Why?
|
| Thiazepines | 1 | 2005 | 1 | 0.020 |
Why?
|
| Vascular Patency | 1 | 2005 | 126 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2005 | 197 | 0.020 |
Why?
|
| Coronary Stenosis | 1 | 2005 | 39 | 0.020 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2005 | 66 | 0.020 |
Why?
|
| Life Tables | 1 | 2004 | 48 | 0.020 |
Why?
|
| Bundle-Branch Block | 1 | 2005 | 48 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 2706 | 0.020 |
Why?
|
| Neurotransmitter Agents | 1 | 2005 | 106 | 0.020 |
Why?
|
| Pulmonary Valve Stenosis | 1 | 2004 | 18 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 1566 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2005 | 190 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2006 | 895 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2005 | 329 | 0.010 |
Why?
|
| Cause of Death | 1 | 2004 | 277 | 0.010 |
Why?
|
| Pyridines | 1 | 2005 | 310 | 0.010 |
Why?
|
| Stents | 1 | 2005 | 377 | 0.010 |
Why?
|
| Cyclosporine | 1 | 2003 | 234 | 0.010 |
Why?
|
| Radiography | 1 | 2004 | 813 | 0.010 |
Why?
|
| Decision Making | 1 | 2006 | 642 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2004 | 2379 | 0.010 |
Why?
|
| Neoplasms | 1 | 2003 | 2898 | 0.000 |
Why?
|